Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma

No abstract is available for this paper.

• Publication year

  2004

• Venue

  British Journal of Haematology

• Publication date

  2004-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2141.2004.04837.xPMID 15009065
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tandem transplants with different high‐dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Español de Síndromes Linfoproliferativos/Trasplante Autólogo de Médula Ósea phase II trial

  2003cited by this paper
• High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

  2003cited by this paper
• The role of stem cell transplantation in multiple myeloma.

  2002cited by this paper
• Myeloablative Treatments for Multiple Myeloma: Update of a Comparative Study of Different Regimens Used in Patients from the Spanish Registry for Transplantation in Multiple Myeloma

  2002influential reference
• Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma

  2001cited by this paper
• Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial.

  2001cited by this paper
• Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma.

  2001cited by this paper
• Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies.

  2001cited by this paper
• Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group.

  2000cited by this paper
• Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma

  2000cited by this paper
• Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study.

  2000cited by this paper
• Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma

  1999cited by this paper
• Total therapy with tandem transplants for newly diagnosed multiple myeloma.

  1999influential reference
• Autologous Peripheral Blood Progenitor Cell Transplantation in Multiple Myeloma

  1999cited by this paper
• High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.

  1998cited by this paper
• Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation.

  1998cited by this paper
• Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

  1997cited by this paper
• A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

  1996cited by this paper
• A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

  1996cited by this paper
• Phase I-II study of busulfan and cyclophosphamide conditioning for transplantation in advanced multiple myeloma.

  1994cited by this paper
• Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide.

  1994cited by this paper
• Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support.

  1992cited by this paper
• Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support

  1992cited by this paper
• High‐dose chemotherapy and autologous bone marrow transplantation for myeloma

  1989influential reference
• Marrow transplantation for malignant plasma cell disorders: Summary of the Seattle experience *

  1989cited by this paper
• High-dose melphalan with autologous bone marrow transplantation for multiple myeloma.

  1986cited by this paper
• High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.

  1983cited by this paper

• Autograft composition and outcome-towards an optimal graft?

  2024cites this paper
• Busulfan and cyclophosphamide for autologous stem cell transplantation in patients with multiple myeloma after proteasome inhibitor and/or immunomodulatory drug treatment

  2024influential citation
• Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial

  2023cites this paper
• The effect of mobilizing large numbers of CD34 + cells (super-mobilizers) on the engraftment and survival in patients undergoing autologous stem cell transplantation.

  2023cites this paper
• Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation

  2023cites this paper
• Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments

  2023influential citation
• Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment

  2023cites this paper
• GPC-100, a novel CXCR4 antagonist, improves in vivo hematopoietic cell mobilization when combined with propranolol

  2023cites this paper
• Autograft cellular composition and outcome in myeloma patients: Results of the prospective multicenter GOA study

  2021influential citation
• CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non‐Hodgkinʼs lymphoma patients: results of the prospective multicenter GOA study

  2020influential citation
• Clinical outcomes of multiple myeloma patients who undergo autologous hematopoietic stem cell transplant with G‐CSF or G‐CSF and plerixafor mobilized grafts

  2020cites this paper
• A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma

  2019cites this paper
• GENESIS: Phase III trial evaluating BL-8040 + G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma.

  2019cites this paper
• Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.

  2018cites this paper
• Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in Japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study

  2018cites this paper
• Blood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor: a prospective multicenter study

  2018cites this paper
• Intravenous compared to oral busulfan with cyclophosphamide for autologous hematopoietic cell transplant conditioning for plasma cell myeloma.

  2018cites this paper
• The relationship of CD34+ dosage and platelet recovery following high dose chemotherapy and autologous CD34+ reinfusion in multiple myeloma.

  2017cites this paper
• Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma

  2017cites this paper
• The high effect of chemomobilization with high-dose topside and G-CSF in autologous hematopoietic peripheral blood stem cell transplantation (Single centre experience)

  2016cites this paper
• The High Effect of Chemomobilization with High-Dose Etopside + Granulocyte-Colony Stimulating Factor in Autologous Hematopoietic Peripheral Blood Stem Cell Transplantation: A Single Center Experience

  2016cites this paper
• Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

  2016cites this paper
• Remobilization of hematopoietic stem cells with high‐dose methotrexate and cytarabine in patients with non‐Hodgkin's lymphoma and multiple myeloma after failure to mobilize with chemotherapy and cytokines

  2014cites this paper
• Efficacy and safety of busulfan-based conditioning regimens for multiple myeloma.

  2013cites this paper
• EfficacyandSafetyofBusulfan-BasedConditioningRegimensfor MultipleMyeloma

  2013cites this paper
• Optimizing stem cell collection through CXCR4 antagonists.

  2012cites this paper
• CD34⁺ cell content in unrelated allogeneic peripheral blood stem cell grafts transported internationally. Does the inter-laboratory variability affect comparability of graft quality data?

  2012cites this paper
• Predictors of non-compliance in autologous hematopoietic SCT patients undergoing out-patient transplants

  2012cites this paper
• Preemptive use of plerixafor in difficult‐to‐mobilize patients: an emerging concept

  2012cites this paper
• [Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma].

  2012cites this paper
• Mobilization with Chemotherapy + G-CSF + Plerixafor in Europe: The Italian Experience

  2012cites this paper
• Die retrospektive Analyse der Wirkung von patientenspezifischen Parametern auf die benötigte Apheresenanzahl und den CD34 + -Ertrag von autologen Stammzellspendern

  2012cites this paper
• The Use of Bortezomib in Autologous Transplantation for Multiple Myeloma

  2011cites this paper
• Reply to J. de la Rubia et al

  2011cites this paper
• Proposed definition of ‘poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo

  2011cites this paper
• Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens

  2011cites this paper
• Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.

  2011cites this paper
• Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.

  2011cites this paper
• Plerixafor and granulocyte–colony‐stimulating factor (G‐CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G‐CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program

  2011cites this paper
• A randomized clinical trial comparing granulocyte–colony‐stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation

  2011cites this paper
• Can every patient be mobilized?

  2010cites this paper
• Mobilization strategies in hard‐to‐mobilize patients with lymphoid malignancies

  2010cites this paper
• BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma

  2009cites this paper
• Improving stem cell mobilization strategies: future directions

  2009cites this paper
• Binding of proteins to PEGylated liposomes and improvement of G-CSF efficacy in mobilization of hematopoietic stem cells.

  2009cites this paper
• Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma

  2009cites this paper
• Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period

  2006cites this paper
• High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma

  2006cites this paper
• Conceptual models to understand tissue stem cell organization

  2004cites this paper
• Motixafortide and G-CSF to mobilize hematopoietic stem cells for Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: A randomized autologous transplantation in multiple myeloma: A randomized

  year unknowncites this paper